PMID- 25416968
OWN - NLM
STAT- MEDLINE
DCOM- 20150818
LR  - 20181113
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 101
IP  - 2
DP  - 2015 Feb
TI  - Effects of factor VIII levels on the APTT and anti-Xa activity under a 
      therapeutic dose of heparin.
PG  - 119-25
LID - 10.1007/s12185-014-1702-z [doi]
AB  - In pregnant women, activated partial thromboplastin time (APTT) does not 
      precisely reflect the anticoagulant effect of a therapeutic dose of heparin. 
      However, the measurement of anti-Xa activity can be used to monitor the 
      anticoagulant effect of heparin, since the plasma concentrations of coagulation 
      factors increase in pregnant women. We evaluated the in vitro effects of 
      increased concentrations of fibrinogen and other coagulation factors (FVII, 
      FVIII, and FIX) on the results of assays of APTT and anti-Xa activity in plasma 
      samples with various therapeutic concentrations of unfractionated heparin (UFH). 
      In the presence of UFH, APTT was shortened by increased concentrations of 
      fibrinogen, FVII, or FVIII, and this effect was much stronger when the FVIII 
      concentration was increased. In the plasma samples containing 0.5 or 0.7 U/mL of 
      UFH, the APTT was shortened by approximately half or one-third, respectively, 
      when 6 U FVIII/mL was added to the sample. The anti-Xa activity was not 
      influenced by increased concentrations of the coagulation factors. In the present 
      study, we also evaluated the sensitivities to UHF of four APTT reagents, and 
      found a 1.65-fold difference in the sensitivity to UFH among APTT reagents. Our 
      results demonstrate that increased FVIII concentration shortens APTT under 
      therapeutic doses of UFH, and that APTT thus underestimates the anticoagulant 
      effect of UFH in pregnant women, mainly due to the increased FVIII concentration.
FAU - Mitsuguro, Mana
AU  - Mitsuguro M
AD  - Laboratory of Clinical Chemistry, National Cerebral and Cardiovascular Center, 
      Suita, Osaka, Japan.
FAU - Okamoto, Akira
AU  - Okamoto A
FAU - Shironouchi, Yoshie
AU  - Shironouchi Y
FAU - Sano, Michitaka
AU  - Sano M
FAU - Miyata, Shigeki
AU  - Miyata S
FAU - Neki, Reiko
AU  - Neki R
FAU - Araki, Tatsuya
AU  - Araki T
FAU - Hamamoto, Takayoshi
AU  - Hamamoto T
FAU - Yoshimatsu, Jun
AU  - Yoshimatsu J
FAU - Miyata, Toshiyuki
AU  - Miyata T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141123
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Factor Xa Inhibitors)
RN  - 9001-25-6 (Factor VII)
RN  - 9001-27-8 (Factor VIII)
RN  - 9001-28-9 (Factor IX)
RN  - 9001-32-5 (Fibrinogen)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Factor IX
MH  - Factor VII
MH  - *Factor VIII
MH  - Factor Xa Inhibitors/*blood
MH  - Female
MH  - Fibrinogen
MH  - Heparin/*administration & dosage/blood
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Partial Thromboplastin Time/*standards
MH  - Sensitivity and Specificity
EDAT- 2014/11/25 06:00
MHDA- 2015/08/19 06:00
CRDT- 2014/11/24 06:00
PHST- 2014/08/26 00:00 [received]
PHST- 2014/11/13 00:00 [accepted]
PHST- 2014/11/10 00:00 [revised]
PHST- 2014/11/24 06:00 [entrez]
PHST- 2014/11/25 06:00 [pubmed]
PHST- 2015/08/19 06:00 [medline]
AID - 10.1007/s12185-014-1702-z [doi]
PST - ppublish
SO  - Int J Hematol. 2015 Feb;101(2):119-25. doi: 10.1007/s12185-014-1702-z. Epub 2014 
      Nov 23.